Year: 2021

CINCINNATI, Dec. 16, 2021 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce record preliminary financial results for the fourth quarter of 2021, ending September 30, 2021 as well as a business update with respect to recent announcements. Record Preliminary Financial Results – Fourth Quarter Ended September 30, 2021Revenue in the range of $27.6 million to $28.1 million Adjusted EBITDA (defined and reconciled below) in the range of $5.3 million to $5.6 million Cash (and cash equivalents) was $34.6 million as of September 30, 2021Business UpdatesOn October 1, 2021, the Company acquired a business with operations in Mississippi, reporting unaudited trailing...

GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses. “Emergent remains focused on investing in our diverse portfolio of R&D programs targeting infectious disease and other public health threats,” said Kelly Warfield, Ph.D., senior vice president, research and development at Emergent BioSolutions. “Initiating this phase 1 study demonstrates our commitment to advancing our pipeline and our research and development...

The 70.0 Net Promoter Score in November indicates PARTS iD has a strong, positive sentiment among customers CRANBURY, N.J., Dec. 16, 2021 (GLOBE NEWSWIRE) — PARTS iD, Inc. (NYSE American: ID) (“PARTS iD” or “Company”), the owner and operator of, among other verticals, “CARiD.com,” a leading digital commerce platform for the automotive aftermarket, today announced that it achieved a Net Promoter Score® (NPS®) of 70.0 during November, its highest monthly score of 2021 thus far. The high November score follows several months of high Net Promoter Scores between 65-70. A company’s NPS measures customer experience and satisfaction by asking customers to rate their likelihood of recommending the brand on a scale of one to ten and subtracting the percentage of detractors (rating 0-6) from the percentage of promoters (rating 9-10). During...

Philadelphia, PA, Dec. 16, 2021 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (OTCQB: VSBGF) (CSE: VSBY) (Frankfurt 5VS) (“VSBLTY”), a leading software provider of security and retail analytics technology, today announced that, in conjunction with RADARApp, the Mexico City county of Magdalena Contreras will be the first to receive an edge cloud hybrid deployment that enables the borough infrastructure to work in synergy with citizen homes to lower crime rates. The Phase One deployment includes smart cameras, using VSBLTY artificial intelligence technology and the industry’s most advanced analytics, being installed in public locations, in addition to other security devices, to create a WiFi6-based surveillance network. The Phase One smart cameras, all of which will be utilizing advanced VSBLTY AI analytics and RADARApp technology,...

COLUMBUS, Ohio, Dec. 16, 2021 (GLOBE NEWSWIRE) — Worthington Industries, Inc. (NYSE: WOR) today reported net sales of $1.2 billion and net earnings of $110.3 million, or $2.15 per diluted share, for its fiscal 2022 second quarter ended Nov. 30, 2021. In the second quarter of fiscal 2021, the Company reported net sales of $731.1 million and a net loss of $74.0 million, or $(1.40) per diluted share. Results in both the current and prior year quarter were impacted by certain unique items, as summarized in the table below. (U.S. dollars in millions, except per share amounts)    2Q 2022     2Q 2021      After-Tax     Per Share     After-Tax     Per Share  Net earnings (loss)   $ 110.3     $ 2.15     $ (74.0 )   $ (1.40 )Impairment and restructuring (gains) charges     (1.5 )     (0.03 )     8.6       0.17  Incremental...

– In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 – – Company announces plans for Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma; IND submission on track for mid-2022 – – Data presented at ASH Annual Meeting support potential for γδ CAR-iT cells to deliver allogeneic T cell therapies without risk for GVHD; γδ cells chosen as initial focus of iT cell development program – – Company to host virtual research & development update today at 8:00 AM ET – PHILADELPHIA, Dec. 16, 2021 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced updated...

CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in heavily pre-treated patients at 100mg BID Encouraging durable responses and progression free survival at 100mg BID CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today reported updated data from the Company’s ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have progressed on or after prior therapy. “The updated data from our ongoing Phase...

– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Data from third patient cohort confirm antifungal activity above pre-defined threshold target for success, while maintaining a desirable overall safety profile – – Enrollment in fourth cohort of patients expected to commence early Q1 2022 – BEDMINSTER, N.J., Dec. 16, 2021 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced that the independent Data and Safety Monitoring Board (DSMB) of the EnACT trial (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial) has completed a prespecified review of the third...